Schiweck Weinzierl Koch Patentanwälte Partnerschaft mbB

In an embodiment of the present invention, a method converts continuous scores from an AI disease classifier into clinically meaningful risk estimates. Historical score-outcome data are binned into percentiles, and the cumulative disease fraction is fitted with a differentiable curve for example a two-Beta mixture. The curve's derivative yields an instantaneous risk ratio that, combined with baseline prevalence, provides an absolute disease malady probability. Risk ratio and absolute probability ensures comparability across model versions, improving interpretability. The invention includes associated systems, software, and computer-readable media.

In an embodiment of the present invention, a method converts continuous scores from an AI disease classifier into clinically meaningful risk estimates. Historical score-outcome data are binned into percentiles, and the cumulative disease fraction is fitted with a differentiable curve for example a two-Beta mixture. The curve's derivative yields an instantaneous risk ratio that, combined with baseline prevalence, provides an absolute disease malady probability. Risk ratio and absolute probability ensures comparability across model versions, improving interpretability. The invention includes associated systems, software, and computer-readable media.

The present application provides a solution for sequencing chip cleaning, a sequencing method, and a kit. The solution for sequencing chip cleaning includes a basic buffer, Na⁺ and/or K⁺, a surfactant, and a pH regulator. The solution further comprises at least one of a divalent cation, NH₄⁺, and a polymerase. In the solution for sequencing chip cleaning provided herein, at least one of a divalent cation, NH₄⁺, and a polymerase is further added on the basis of the basic buffer, Na⁺ and/or K⁺, the surfactant, and the pH regulator, such that, after a sequencing chip is cleaned by using the solution, the solution remaining on the sequencing chip can play a buffering role and provide a stable reaction environment for the incorporation of nucleotides or nucleotide analogs into nucleic acid templates when the sequencing chip is used for sequencing, thereby improving the reaction efficiency of incorporating nucleotides or nucleotide analogs into nucleic acid templates, further reducing the phasing, and improving the sequencing accuracy.

The present application discloses a variety of amplification methods and reagent kits. In an amplification method provided in the present application, a first cycle of amplification is performed on a target polynucleotide through steps S20-S40, and an extended strand of a first amplification primer is generated on the surface of a solid carrier; then, amplification is performed on the extended strand of the first amplification primer through steps S60-S100, and an extended strand of a second amplification primer is generated on the surface of the solid carrier; subsequently, the extended strand of the first amplification primer and the extended strand of the second amplification primer are used as templates to perform cyclic amplification according to steps S120-S160 to obtain a molecular cluster of the target polynucleotides, so as to amplify signals generated by incorporating nucleotides or nucleotide analogs into the target polynucleotides in the process of sequencing the target polynucleotides, thereby making it easier to detect the signals and improving the efficiency and accuracy of signal detection. Meanwhile, by configuring at least one of betaine having a concentration greater than 0 mol/L and less than or equal to 4 mol/L, Mg<2+> having a concentration of 0.5-4 mmol/L, NH<4>+ having a concentration greater than 0 mmol/L and less than or equal to 100 mmol/L, and formamide having a percent concentration by volume (vol/vol% or v/v%) less than or equal to 15% in each of a first solution, a second solution, and a fourth solution, the amplification method provided in the present application can reduce the formation of a secondary structure in the template molecule, improve amplification efficiency, and facilitate the binding of the template molecule to the amplification primer and the extension of the amplification primer, thereby reducing GC bias.

The present invention provides peptides useful as epitope tags, which may be fused to a polypeptide of interest, as well as antibodies that specifically bind to these peptides. The peptides and/or antibodies can be used for detecting, immobilizing, isolating or purifying a molecule that is conjugated to such a peptide and/or antibody.

Provided are a potentiometric biosensor (100) and a method for detecting urea concentration in a sample. The potentiometric biosensor (100) comprises an indication electrode (23) and a reference electrode (24). A second reaction reagent on the indication electrode (23) comprises a urease but does not comprise an electron transporter. A first reaction reagent on the reference electrode (24) comprises an electron transporter but does not comprise a urease. In the case where no external voltage is applied, after a blood sample has been added, the urease catalyzes the reaction of urea in the sample, thereby causing a potential difference between the indication electrode (23) and the reference electrode (24). Furthermore, the potential difference between the indication electrode (23) and the reference electrode (24) is in a linear relationship with the urea concentration in the sample, and the urea concentration in the sample can be calculated according to such linear relationship.

Disclosed herein are methods and compositions for detecting one or more pathogens that cause atypical pneumonia. Detectable pathogens include Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Legionella pneumophila.

The present application relates to the field of sequencing image data processing technology, and in particular, to a method for detecting an abnormal region in an image, a method for base calling by processing an abnormal region in an image, and a related device. In the present application, the abnormal region is identified by analyzing the intensity of the pixel where the position of the nucleic acid template is located in the image of interest and the brightness of image blocks in the image of interest, and the intensity of the position of the nucleic acid template in the abnormal region is zeroed, so as to identify the base type of the nucleic acid template incorporated into the abnormal region in the sequencing process as unknown, thereby eliminating the abnormal signal interference and improving the accuracy of base sequencing.

The present invention relates to a bispecific antibody construct for use in treating non-small cell lung cancer (NSCLC) in a subject, optionally in combination with an immune checkpoint inhibitor, wherein the bispecific antibody construct is administered in a loading dose for a first period of time, and is then administered in a maintenance dose for a second period of time, wherein the loading dose is higher than the maintenance dose. Also provided are compositions comprising an immune checkpoint inhibitor and a bispecific antibody construct and there use in treating non-small cell lung cancer (NSCLC) in a subject and methods of stratifying and treating a tumor patient, comprising determining the type of tumor of the patient, and electing patients diagnosed with NSCLC for treatment with the bispecific antibody construct.

The invention relates to a bispecific antibody construct, a taxane, and/or an immune checkpoint inhibitor for use in a method of treating a tumor in a subject, wherein the bispecific antibody construct comprises at least one first binding domain capable of specifically binding CD16A and at least one second binding domain capable of specifically binding EGFR, wherein the method comprises administering to the subject the bispecific antibody construct, the taxane, and the immune checkpoint inhibitor. The invention further relates to a composition comprising a taxane and a bispecific antibody construct that comprises at least one first binding domain capable of specifically binding CD16A and at least one second binding domain capable of specifically binding EGFR.